FIGURE 1.

Time of FDA approval of ICIs in solid tumours (https://www.fda.gov/drugs, accessed November 14, 2019). Abbreviations: 1 = first line; 2 = second line; 3 = third line; A = any line; RCC = renal cell carcinoma; NSCLC = non‐small cell lung cancer; non‐squam = non‐squamous; PDL1 = programmed death‐ligand 1; HNSCC = head and neck squamous cell carcinoma; MSI‐H = microsatellite instability‐high; dMMR = deficient mismatch repair; Met = metastatic; HCC = hepatocellular carcinoma; GEJ = gastroesophageal; SCC = squamous cell carcinoma; HR/IR = high risk/intermediate risk; ES SCLC = extensive stage small cell lung cancer; TNBC = triple negative breast cancer